



UNITED STATES PATENT AND TRADEMARK OFFICE

JAN 22 2001

Commissioner for Patents  
United States Patent and Trademark Office  
Washington, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

Charles W. Ashbrook  
Assistant General Counsel, Pharmaceutical Patents  
WARNER-LAMBERT COMPANY  
Parke-Davis Pharmaceutical Research Division  
2800 Plymouth Road/Ann Arbor MI 48105

Re: Patent Term Extension  
Application for  
U.S. Patent No. 4,935,507

21

Dear Mr. Ashbrook:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 4,935,507 for a period of 1,213 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products).

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson

Karin Tyson  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Assistant Commissioner for Patent Examination Policy

cc: David T. Read  
Acting Director Regulatory Pol  
Food and Drug Administration  
1451 Rockville Pike, HFD-7  
Rockville, MD 20852

Re: OMNICEF® Oral Suspension (cefdinir)  
 FDA Docket No. 98E-0840

#21

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE EXTENDING PATENT TERM  
UNDER 35 U.S.C. § 156

PATENT NO. : 4,935,507  
ISSUED : June 19, 1990  
INVENTORS : Takao Takaya, et al.  
PATENT OWNER : Fujisawa Pharmaceutical Co., Ltd.  
PRODUCT : OMNICEF® Oral Suspension (cefdinir)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the U.S. Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 4,935,507 based upon the regulatory review of the product OMNICEF® Oral Suspension (cefdinir) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

1,213 days

from August 8, 2008, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the U.S. Patent and Trademark Office to be affixed this 19th day of January 2001.

A handwritten signature in black ink, appearing to read "Q. Todd Dickinson".

Q. Todd Dickinson

Under Secretary of Commerce for Intellectual Property and  
Director of the United States Patent and Trademark Office